- Appendix 4C & Quarterly Business Update – March 2024
- Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering
- Genetic Technologies Announces $2 Million Registered Direct Offering
- New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes
- GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year
- GTG to pilot GeneType in Breast Screen centers across the U.S.
- EVENT - Empowering Women Through Knowledge; Humanise Health & GeneType Launch "Know Your Risk”
- Genetic Technologies’ Digital Strategy Ignites Significant Traction in US Market
- GTG Global Collaborations and Innovation Update
- GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare
More ▼
Key statistics
As of last trade, Genetic Technologies Ltd (GTG:ASX) traded at 0.12, 29.03% above the 52 week low of 0.093 set on Jan 23, 2024.
52-week range
Open | 0.12 |
---|---|
High | 0.12 |
Low | 0.115 |
Bid | 0.11 |
Offer | 0.12 |
Previous close | 0.12 |
Average volume | 140.10k |
---|---|
Shares outstanding | 132.22m |
Free float | 118.56m |
P/E (TTM) | -- |
Market cap | 15.87m AUD |
EPS (TTM) | -0.1126 AUD |
Data delayed at least 20 minutes, as of May 02 2024 04:39 BST.
More ▼